The 9th edition of DDup is dedicated to our unique and innovative iPSC-based drug discovery programme TargetRD (Retinal Disease), which we have developed in collaboration with our colleagues from the Centre for Regenerative Therapies TU Dresden. 

Evotec’s intention with the TargetRD programme is to support the fight against retinopathies like age-related macular degeneration (AMD), a leading cause of blindness globally associated with very limited treatment options. With this DDup we show that our iPSC-based approach delivers more predictive models with a considerably better chance of successful clinical translation.